Loading...
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert, C Dummer, R Gutzmer, R Lorigan, Paul C Kim, K Nyakas, M Arance, A Liszkay, G Schadendorf, D Cantarini, M
Robert, C
Dummer, R
Gutzmer, R
Lorigan, Paul C
Kim, K
Nyakas, M
Arance, A
Liszkay, G
Schadendorf, D
Cantarini, M
Citations
Altmetric:
Abstract
Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when combined with chemotherapy. This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with dacarbazine alone.
Description
Date
2013-07
Publisher
Collections
Keywords
Type
Article
Citation
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. 2013, 14 (8):733-40 Lancet Oncol